Sue Rochman, MA

All articles by Sue Rochman, MA

The discovery that tumors in myeloma have immunogenic antigens provides a rationale for the development of neoantigen-based therapeutic vaccines.

Multiple Myeloma

The Quest for a Personalized Genomic Vaccine in Myeloma

By

Sue Rochman, MA

February 27, 2020

The discovery that tumors in myeloma have immunogenic antigens provides a rationale for the development of neoantigen-based therapeutic vaccines.

Next post in Multiple Myeloma

Patterns of Cadiotoxicity Associated With Carfilzomib

Study Supports Less Frequent Dosing of Bortezomib in Multiple Myeloma